Clinical Trials Logo

Small Lymphocytic Leukemia clinical trials

View clinical trials related to Small Lymphocytic Leukemia.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04018248 Active, not recruiting - Clinical trials for Chronic Lymphocytic Leukemia

BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I)

Start date: April 21, 2020
Phase: Phase 1
Study type: Interventional

This is a Phase I-II, multi-center, open-label, FIH study comprising of 2 study parts (Phase Ia, Phase Ib). The Phase Ia (dose escalation) part of the study is designed to determine the safety, tolerability, and maximum tolerated dose (MTD)/recommended dose for expansion (RP2D) of BR101801 in subjects with relapsed/refractory B cell lymphoma, chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL), and peripheral T cell lymphoma (PTCL). The Phase Ib (dose expansion) part of the study is designed to assess tumor response and safety in specific advanced relapsed/refractory Peripheral T-cell lymphoma(PTCL) at a dose of BR101801 identified in Phase Ia. Once the RP2D has been determined in Phase Ia (dose escalation), Phase Ib (dose expansion) will commence.

NCT ID: NCT03207555 Active, not recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)

Start date: May 23, 2018
Phase: Phase 2
Study type: Interventional

The standard approach to managing chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) is to wait until you have symptoms before treatment is given. The goal of this clinical research study is to learn if providing earlier treatment for CLL or SLL with ibrutinib in patients who do not have symptoms will be more effective than waiting until symptoms develop. This is an investigational study. Ibrutinib is FDA approved and commercially available for the treatment of patients with CLL or SLL. It is considered investigational to give ibrutinib to CLL and SLL patients before symptoms develop. The study doctor can describe how the study drug is designed to work. Up to 50 participants will be enrolled in this study. All will take part at MD Anderson.

NCT ID: NCT00109356 Active, not recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Study of AQ4N in Patients With Non Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Leukemia

Start date: March 2005
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to find answers to the following questions: - What is the largest dose of AQ4N that can be given safely one time every three weeks for 24 weeks? - What are the side effects of AQ4N when given according to this schedule? - How much AQ4N is in the blood at certain times after administration and how does the body get rid of the drug? - Will AQ4N help treat lymphoid cancer?